Alector Inc (ALEC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alector Inc (ALEC) has a cash flow conversion efficiency ratio of -1.360x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.69 Million) by net assets ($30.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Alector Inc to measure how much of total assets are equity-financed.
Alector Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Alector Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Alector Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Alector Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alector Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nice Information & Telecommunication Inc
KQ:036800
|
0.088x |
|
Core Molding Technologies Inc
NYSE MKT:CMT
|
0.032x |
|
Verkkokauppa.com Oyj
HE:VERK
|
-0.010x |
|
Lucara Diamond Corp
TO:LUC
|
0.083x |
|
CareRx Corp
TO:CRRX
|
0.057x |
|
Mayfair Gold Corp
V:MFG
|
-0.147x |
|
AAPICO Hitech Public Company Limited
BK:AH
|
0.036x |
|
Hanover Bancorp Inc
NASDAQ:HNVR
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Alector Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Alector Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Alector Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $30.65 Million | $-184.03 Million | -6.004x | -231.17% |
| 2024-12-31 | $126.80 Million | $-229.91 Million | -1.813x | -32.08% |
| 2023-12-31 | $134.16 Million | $-184.16 Million | -1.373x | -1348.03% |
| 2022-12-31 | $214.44 Million | $-20.33 Million | -0.095x | -109.55% |
| 2021-12-31 | $300.72 Million | $298.55 Million | 0.993x | +259.29% |
| 2020-12-31 | $267.53 Million | $-166.73 Million | -0.623x | -22.22% |
| 2019-12-31 | $194.74 Million | $-99.31 Million | -0.510x | +61.03% |
| 2018-12-31 | $-97.40 Million | $127.46 Million | -1.309x | -483.18% |
| 2017-12-31 | $-52.03 Million | $-17.77 Million | 0.342x | -34.53% |
| 2016-12-31 | $-24.91 Million | $-12.99 Million | 0.522x | -- |
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheim… Read more